Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study.
Detection of unrecognized low-level mtDNA heteroplasmy may explain the variable phenotypic expressivity of apparently homoplasmic mtDNA mutations.
[Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].
Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness.
Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load.
Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.
Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity.
A multidisciplinary approach for the identification of novel HIV-1 non-nucleoside reverse transcriptase inhibitors: S-DABOCs and DAVPs.
Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.